Core Viewpoint - The company has achieved its first profitability and secured a significant contract worth nearly $6 billion, validating its AI pharmaceutical commercialization capabilities [1][2]. Group 1: Financial Performance - In the first half of 2025, the company reported revenue of 517 million yuan, a year-on-year increase of 403.8% [1]. - The adjusted net profit reached 141.6 million yuan, marking the first half-year profitability for the company [1]. Group 2: Strategic Partnerships - The company signed a final cooperation agreement with DoveTree Medicines LLC, initiating an end-to-end AI drug discovery strategic partnership [2]. - The agreement allows the company to receive an initial payment of $51 million, with potential milestone payments totaling up to $5.89 billion [2]. Group 3: Capital Raising and Utilization - The company completed a new round of placement, raising 2.6533 billion HKD, which represents 6.64% of the expanded issued share capital [3]. - The raised funds will be allocated as follows: 40% for product iteration and R&D enhancement, 30% for commercialization and business expansion, and 30% for investments, talent acquisition, and funding supplementation [3].

Group 1 - The core point of the article is that JingTai Holdings (02228) has seen a significant stock price increase following its inclusion in the FTSE China Small Cap Index, indicating greater capital attention and liquidity premium [1][1] - As of the report, JingTai Holdings' stock rose over 5%, trading at 11.03 HKD with a transaction volume of 1.487 billion HKD [1][1] - The inclusion in the FTSE index became effective after the market close on September 19, which is expected to enhance the company's visibility and attract more investors [1][1] Group 2 - According to招商证券, JingTai Technology's AI pharmaceutical business is progressing steadily, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1][1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1][1] - JingTai has signed a pipeline cooperation agreement with DoveTree, with a total order scale of 5.99 billion USD, receiving an initial payment of 51 million USD, which is expected to contribute positively to its performance [1][1] - The company has successfully expanded its technology platform into various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physics computing, multimodal AI, and automation platforms [1][1]

Group 1 - The core point of the article highlights that Crystal Tech Holdings (02228) saw a significant stock price increase, rising over 5% and reaching HKD 11.03, with a trading volume of HKD 1.487 billion [1] - Crystal Tech Holdings has been included in the FTSE China Small Cap Index as part of the FTSE Russell Index Company's semi-annual adjustments, effective after the market close on September 19 [1] - Inclusion in an international index indicates broader capital attention and liquidity premium for the company [1] Group 2 - According to招商证券, Crystal Tech's AI pharmaceutical business is steadily advancing towards commercialization, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - Crystal Tech has signed a pipeline cooperation agreement with DoveTree, with a total order scale of USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] Group 3 - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physical computing, multimodal AI, and automation platforms [1]

Group 1 - The stock of Jingtai Technology (02228.HK) in Hong Kong increased by over 5% on September 18, reaching a rise of 5.06% [1] - The stock price was reported at 10.37 HKD at the time of publication [1] - The trading volume amounted to 964 million HKD [1]

Core Viewpoint - JingTai Technology (02228) has seen a stock increase of over 5% following the announcement of a significant clinical development milestone for the new generation PRMT5 inhibitor PEP08, which has received clinical trial approvals in Australia and Taiwan [1] Group 1: Clinical Development - JingTai Technology announced that the PRMT5 inhibitor PEP08 has achieved important clinical research milestones, receiving approvals from the Human Research Ethics Committee (HREC) in Australia, the Therapeutic Goods Administration (TGA), and the Taiwan Food and Drug Administration (TFDA) for clinical trials [1] - The initiation of Phase I clinical trials for PEP08 is imminent, marking a significant step in its development [1] Group 2: Financial Performance - JingTai Technology confirmed receipt of milestone payments related to the PEP08 project, contributing positively to its financial performance [1] - According to招商证券, the company's AI pharmaceutical business is steadily advancing, with a projected year-on-year growth rate of 615% in drug discovery business by the first half of 2025 [1] Group 3: Strategic Partnerships - The company has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - JingTai Technology has completed a pipeline cooperation agreement with DoveTree, with a total order scale of 5.99 billion USD, and has received an initial payment of 51 million USD as per the agreement [1] Group 4: Technological Advancements - The company has successfully expanded its technology platform across various fields, including new energy, agriculture, and industrial materials, by leveraging quantum physics computing, multimodal AI, and automation platforms [1]

Core Viewpoint - Crystal Technology (02228) has seen a stock increase of over 5% following the announcement of a significant clinical development milestone for the new generation PRMT5 inhibitor PEP08, which has received clinical trial approvals in Australia and Taiwan [1] Group 1: Company Developments - Crystal Technology's stock rose by 5.06%, reaching HKD 10.37, with a trading volume of HKD 964 million [1] - The company confirmed receipt of milestone payments related to the PEP08 project, which is set to enter Phase I clinical trials [1] - The AI pharmaceutical business of Crystal Technology is progressing steadily, with a projected year-on-year growth rate of 615% in drug discovery by the first half of 2025 [1] Group 2: Collaborations and Financials - Crystal Technology has established long-term collaborations with leading global pharmaceutical companies such as Pfizer and Johnson & Johnson [1] - The company signed a pipeline cooperation agreement with DoveTree, totaling USD 5.99 billion, and has received an initial payment of USD 51 million, contributing positively to its performance [1] - The company has successfully expanded its technology platform into various fields, including new energy, agriculture, and industrial materials, through the sharing of quantum physics computing, multimodal AI, and automation platforms [1]

XtalPi Holdings Limited 晶泰控股有限公司 股份代號:2228 (於開曼群島註冊成立之有限公司) 2025 中期報告 2025 INTERIM REPORT Stock Code:2228 XtalPi Holdings Limited 晶泰控股有限公司 (Incorporated in the Cayman Islands with limited liability) INTERIM REPORT 2025 中期報告 目錄 公司資料 財務摘要 公司簡介 管理層討論與分析 14 企業管治及其他資料 23 中期財務資料的審閱報告 32 簡明合併損益表 33 簡明合併全面收益表 34 簡明合併資產負債表 35 簡明合併權益變動表 37 簡明合併現金流量表 39 中期財務資料附註 40 2 4 5 釋義 68 公司資料 董事會 執行董事 溫書豪博士 （主席） 馬健博士 （首席執行官） 賴力鵬博士 蔣一得博士 獨立非執行董事 提名委員會 溫書豪博士 （主席） 羅卓堅先生 陳穎琪女士 聯席公司秘書 劉石梅女士 陳秀玲女士 羅卓堅先生 陳穎琪女士 周明笙先生 授權代表 溫書豪博士 劉石梅女士 審核 ...

[XtalPi Holdings Limited Clarification Announcement on Interim Results for the Six Months Ended June 30, 2025](index=1&type=section&id=XtalPi%20Holdings%20Limited%20Clarification%20Announcement) [Purpose and Background of Announcement](index=1&type=section&id=Purpose%20and%20Background%20of%20Announcement) XtalPi Holdings Limited issued this clarification announcement to correct inadvertent clerical errors regarding share count and earnings per share in its interim results announcement published on August 27, 2025 - This announcement aims to correct inadvertent clerical errors in the interim results announcement[4](index=4&type=chunk) [Details of Financial Data Corrections](index=1&type=section&id=Details%20of%20Financial%20Data%20Corrections) This chapter details key financial data corrections in the interim results announcement, primarily concerning the weighted average number of ordinary shares outstanding and basic and diluted earnings per share, with before-and-after comparisons Key Financial Data Correction Comparison (For the Six Months Ended June 30, 2025) | Metric | Original Data | Corrected Data | Change | Reference Page (Interim Results Announcement) | | :--- | :--- | :--- | :--- | :--- | | Weighted Average Number of Ordinary Shares Outstanding (thousand shares) | 5,490,546 | 3,595,629 | Decreased by 34.5% | 24, 25 | | Diluted Weighted Average Number of Ordinary Shares Outstanding (thousand shares) | 5,656,621 | 3,761,704 | Decreased by 33.5% | 25 | | Basic Earnings Per Share (RMB cents) | 1.51 | 2.30 | Increased by 52.3% | 14, 24, 25 | | Diluted Earnings Per Share (RMB cents) | 1.46 | 2.20 | Increased by 50.7% | 14, 24, 25 | [Revised Condensed Consolidated Income Statement](index=2&type=section&id=Revised%20Condensed%20Consolidated%20Income%20Statement) Earnings/(Loss) Per Share Attributable to Equity Holders of the Company | Metric | 2025 (RMB cents) | 2024 (RMB cents) | | :--- | :--- | :--- | | Basic Earnings/(Loss) Per Share | 2.30 | (169.65) | | Diluted Earnings/(Loss) Per Share | 2.20 | (169.65) | [Revised Basic Earnings Per Share Calculation](index=2&type=section&id=Revised%20Basic%20Earnings%20Per%20Share%20Calculation) Basic Earnings/(Loss) Per Share Calculation (For the Six Months Ended June 30) | Metric | 2025 (RMB thousands/thousand shares/RMB cents) | 2024 (RMB thousands/thousand shares/RMB cents) | | :--- | :--- | :--- | | Profit/(Loss) Attributable to Equity Holders of the Company | 82,795 | (1,237,016) | | Weighted Average Number of Ordinary Shares Outstanding (thousand shares) | 3,595,629 | 729,148 | | Basic Earnings/(Loss) Per Share | 2.30 | (169.65) | [Revised Diluted Earnings Per Share Calculation](index=3&type=section&id=Revised%20Diluted%20Earnings%20Per%20Share%20Calculation) Diluted Earnings Per Share Calculation (For the Six Months Ended June 30, 2025) | Metric | Amount (RMB thousands/thousand shares/RMB cents) | | :--- | :--- | | Profit Attributable to Equity Holders of the Company | 82,795 | | Weighted Average Number of Ordinary Shares Outstanding (thousand shares) | 3,595,629 | | Adjustments for Share Options and Share Awards (thousand shares) | 166,075 | | Weighted Average Number of Ordinary Shares for Diluted EPS Calculation (thousand shares) | 3,761,704 | | Diluted Earnings Per Share | 2.20 | [Other Information and Subsequent Disclosure](index=3&type=section&id=Other%20Information%20and%20Subsequent%20Disclosure) All other information in the interim results announcement remains unchanged except for the aforementioned corrections, and profit attributable to equity holders of the company is also unchanged; the adjusted financial data will be included in the upcoming interim report - All other information and content in the interim results announcement remain unchanged, except for the aforementioned adjustments[7](index=7&type=chunk) - The unaudited profit attributable to equity holders of the company for the six months ended June 30, 2025, remains unchanged at **RMB 82,795,000**[7](index=7&type=chunk) - The Group's interim financial information, including the above adjustments, will be incorporated and disclosed in the company's interim report for the six months ended June 30, 2025[7](index=7&type=chunk) [Board of Directors Information](index=3&type=section&id=Board%20of%20Directors%20Information) The announcement concludes by listing the members of XtalPi Holdings Limited's Board of Directors, including executive and independent non-executive directors - The Board of Directors includes Executive Directors Dr. Shuhao Wen, Dr. Jian Ma, Dr. Lipeng Lai, Dr. Yide Jiang, and Independent Non-executive Directors Mr. Cheuk Kin Lo, Ms. Wing Ki Chan, and Mr. Ming Sang Chow[7](index=7&type=chunk)

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases and decreases in ownership percentages for various companies [1][2]. Group 1: Increased Holdings - Heng Rui Medicine (01276) saw the largest increase in ownership percentage, rising by 1.49% to a total of 13.84% [2]. - Kanglong Chemical (03759) experienced a 1.35% increase, bringing its ownership to 60.51% [2]. - Zhaoyan New Drug (06127) increased by 1.27%, reaching a holding of 43.70% [2]. - Other companies with significant increases include Junshi Biosciences (01877) at +1.24% (59.08%) and China Pacific Insurance (02601) at +1.20% (44.16%) [2]. Group 2: Decreased Holdings - Shandong Molong (00568) had the largest decrease, with a drop of 1.99% to 57.67% [2]. - Yisou Technology (02550) decreased by 0.99%, now holding 37.95% [2]. - Nanjing Panda Electronics (00553) saw a reduction of 0.98%, bringing its ownership to 42.65% [2]. - Other notable decreases include Kailai Ying (06821) at -0.95% (43.35%) and Meizhong Jiahe (02453) at -0.95% (32.06%) [2]. Group 3: Five-Day Changes - In the last five trading days, China Merchants Energy (01138) had the highest increase in ownership, up by 6.19% to 65.63% [3]. - Shandong Molong (00568) also saw a significant increase of 3.74% [3]. - Other companies with notable increases include Zhongchu Innovation (03931) at +3.62% (10.35%) and Youbao Online (02429) at +3.33% (17.38%) [3]. Group 4: Twenty-Day Changes - Over the past twenty days, Anjiren Food (02648) experienced the largest increase, up by 12.29% to 20.54% [4]. - China Merchants Energy (01138) also saw a significant increase of 9.07% [4]. - Other companies with notable increases include Yimai Sunshine (02522) at +7.70% (43.02%) and Lens Technology (06613) at +7.56% (13.64%) [4].

Investment Rating - The report gives a "Strong Buy" rating for the company [6][7]. Core Insights - The company leverages quantum physics, artificial intelligence, and automation to drive drug and material research, establishing a data-driven technological barrier and gaining recognition from multinational pharmaceutical companies [1][6]. - The company has shown significant revenue growth, with a projected revenue of 2.66 billion RMB in 2024, a 53% year-on-year increase, and a remarkable 404% growth in the first half of 2025 [6][20]. - The company has secured a pipeline cooperation order worth 5.99 billion USD with DoveTree, indicating strong commercial potential [6][20]. Summary by Sections Company Overview - The company was founded in 2015, focusing on drug discovery and material design using quantum physics and AI technologies [11][12]. - It has established long-term strategic partnerships with major pharmaceutical companies, including Pfizer [12][18]. Industry Development - The AI for Science sector is expected to grow significantly, with applications across various high-tech fields, including drug discovery and materials science [25][28]. - The global AI solutions market is projected to grow from 139.5 billion USD in 2022 to 1,414.2 billion USD by 2030, with a CAGR of 33.5% [31][32]. Main Business Analysis - The company’s core business includes AI-driven drug discovery and intelligent automation solutions, with a focus on small molecules and new materials [19][20]. - The revenue from drug discovery solutions is expected to grow significantly, with a 615% increase in the first half of 2025 compared to the previous year [6][20]. Financial Forecast - The company anticipates revenues of 7.86 billion RMB in 2025, 9.75 billion RMB in 2026, and 14.07 billion RMB in 2027, with adjusted net profits gradually improving [6][8].